pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
sniff results

“Pfizer”

776 total hits · 12 drugs · 2 companies · 0 diseases · 681 catalysts · 81 news

Drugs(12)

expand →
Marketed
Aminophylline Pfizer
Aminophylline · aminophylline [INN]
Asthma
Marketed
Bleomycin Sulfate Pfizer
Bleomycin Sulfate · bleomycin sulfate
Cervical Cancer
Marketed
Bortezomib Pfizer
Bortezomib · bortezomib
Mantle Cell Lymphoma
Marketed
Carboplatin Pfizer
Carboplatin · carboplatin
Metastatic Ovarian Cancer
Marketed
Cytarabine Pfizer
Cytarabine · cytarabine
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Marketed
Dobutamine Hydrochloride Pfizer
Dobutamine Hydrochloride · dobutamine hydrochloride
Congestive Heart Failure (Heart Failure)
Marketed
Furosemide Pfizer
Furosemide · furosemide
Hepatic Edema
Marketed
Gentamicin Sulfate Pfizer
Gentamicin Sulfate · gentamicin sulfate
Bacterial Respiratory Tract Infections
view all 12 drug results →

🐶 Companies(2)

expand →
  • PFIZER
  • $PFEPFIZER INC

Catalysts(681)

expand →
view all 681 catalyst results →

News(81)

expand →
  • Pfizer India site closure risks exacerbating cancer drug shortages↗
    Pfizer has been forced to temporarily close a cancer drug factory in India. The factory won’t reopen for up to two years and is already contributing to cancer drug shortages. In July, heavy monsoon…
    endpoints · 2d ago
  • Alphabet’s GV is one of biotech’s most influential corporate investors↗
    The corporate investor arms of Eli Lilly, Sanofi and Pfizer have participated in billions worth of venture capital rounds, but GV is the industry’s biggest spender.
    biospace · 3d ago
  • #ESMO26: Pfizer looks beyond lung cancer flop as BioNTech, Bristol Myers show early activity↗
    MADRID — Pfizer is moving past its late-stage loss in non-small cell lung cancer, pointing to a post-hoc analysis of earlier-line patients who appear to benefit. Also on Sunday, BioNTech and Bristo…
    endpoints · 5d ago
  • Pfizer details mixed Lyme disease vaccine data↗
    New data on a closely watched Lyme disease vaccine from Pfizer and Valneva provide details on the near-miss in one of two analyses, as the vaccine's commercial future hangs in the balance. Unveiled…
    endpoints · 8d ago
  • Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO↗
    Pfizer halts Phase 2 autoimmune trial: The study was testing a program called PF-06835375 in the rare autoimmune disorder primary immune thrombocytopenia. The federal clinical trials database noted…
    endpoints · 10d ago
  • Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain↗
    Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset.
    fiercebiotech · 10d ago
  • Ambrose Healthcare inks $181M deal for former Pfizer target AM-Pharma↗
    Ambrose Healthcare has bought AM-Pharma for up to 161 million euros, inking a cut-price deal for a biotech once courted by Pfizer.
    fiercebiotech · 14d ago
  • Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’↗
    The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglu…
    biospace · 16d ago
  • view all 81 news results →
    Feb 25, 2040
    phase readout
    in 13y
    Phase 3 primary completion: Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
    →
    Dec 30, 2030
    phase readout
    in 4y
    Phase 3 primary completion: A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
    →
    Jun 14, 2030
    phase readout
    in 4y
    Phase 3 primary completion: Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung…
    →
    Mar 23, 2030
    phase readout
    in 3y
    Trial primary completion: A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
    →
    Feb 23, 2030
    phase readout
    in 3y
    Phase 3 primary completion: Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
    →
    Aug 31, 2027
    phase readout
    in 10mo
    Phase 1 primary completion: A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
    →
    Feb 26, 2027
    phase readout
    in 4mo
    Phase 2 primary completion: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
    →
    Nov 3, 2026
    earnings
    in 4d
    PFIZER INC earnings
    PFIZER INC
    →
    $PFE29.95+1.70%